Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619040 | 1.00 | ANPEP (0.41) | ANPEPERAP2ERAP1TSHRCYP3A4 | |
| SCHEMBL171329 | 0.98 | MEN1 (0.43) | ANPEPERAP2ERAP1TSHRCYP3A4 | |
| SCHEMBL1619039 | 0.83 | ANPEP (0.38) | ANPEPERAP2ERAP1TSHRCYP3A4 | |
| SCHEMBL8558131 | 0.81 | USP2 (0.47) | ANPEPERAP2ERAP1TSHRCYP3A4 | |
| SCHEMBL8558133 | 0.81 | USP2 (0.47) | ANPEPERAP2ERAP1TSHRCYP3A4 | |
| SCHEMBL7360096 | 0.81 | ANPEP (0.37) | ANPEPERAP2ERAP1TSHRCYP3A4 | |
| SCHEMBL1674470 | 0.78 | MEN1 (0.55) | ANPEPERAP2TSHRCYP2D6MEN1 | |
| SCHEMBL31391687 | 0.76 | KMT2A (0.42) | ANPEPERAP2CYP2D6MEN1KMT2A | |
| SCHEMBL12381528 | 0.75 | — | — | |
| SCHEMBL12714698 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094673-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8461191-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110160259-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7842815-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| CN-101583606-A | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY INC (US) | 2009-11-18 | — | — | CN | disclosed |
| EP-2094673-A1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Discovery, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080306127-A9 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008060569-A1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20070161690-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306127-A9 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | ANPEP 3902/4885ERAP2 2566/4885ERAP1 1890/4885 |
| US-20070161690-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | ANPEP 3902/4885ERAP2 2566/4885ERAP1 1890/4885 |
| US-20110160259-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL3, BCL2, BCLAF1 | ANPEP 3902/4885ERAP2 2566/4885ERAP1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.